Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2011

  1. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24 h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate- resistant Staphylococcus aureus

    International Journal of Antimicrobial Agents, Vol. 37, Núm. 4, pp. 332-338

2010

  1. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2 μg/mL

    International Journal of Antimicrobial Agents, Vol. 35, Núm. 2, pp. 131-137